Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration

Gene therapy mediated by recombinant adeno-associated virus (AAV) vectors is a promising treatment for systemic monogenic diseases. However, vector immunogenicity represents a major limitation to gene transfer with AAV vectors, particularly for vector re-administration. Here, we demonstrate that syn...

Descripción completa

Detalles Bibliográficos
Autores principales: Meliani, Amine, Boisgerault, Florence, Hardet, Romain, Marmier, Solenne, Collaud, Fanny, Ronzitti, Giuseppe, Leborgne, Christian, Costa Verdera, Helena, Simon Sola, Marcelo, Charles, Severine, Vignaud, Alban, van Wittenberghe, Laetitia, Manni, Giorgia, Christophe, Olivier, Fallarino, Francesca, Roy, Christopher, Michaud, Alicia, Ilyinskii, Petr, Kishimoto, Takashi Kei, Mingozzi, Federico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173722/
https://www.ncbi.nlm.nih.gov/pubmed/30291246
http://dx.doi.org/10.1038/s41467-018-06621-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173722/
https://www.ncbi.nlm.nih.gov/pubmed/30291246
http://dx.doi.org/10.1038/s41467-018-06621-3

Ejemplares similares